Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost

American Journal of Ophthalmology

Volumn 135, Issue 3, 2003, Pages 314-320

  Stewart, William C ^a,b   Kolker, Allan E ^c   Stewart, Jeanette A ^a   Leech, Jessica ^a   Jackson, Angi L ^a  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Glaucoma Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

ADULT; ALLERGY; ARTICLE; BIOMICROSCOPY; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; EYE DISEASE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OCULAR PRURITUS; OUTCOMES RESEARCH; PHOTOGRAPHY; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SIDE EFFECT; SORE THROAT; STATISTICAL SIGNIFICANCE;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; CONJUNCTIVA; CONJUNCTIVAL DISEASES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPEREMIA; INTRAOCULAR PRESSURE; LIPIDS; MALE; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TIME FACTORS;

EID: 0037374424     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(02)01980-3     Document Type: Article

References (15)

1. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma a six-month, masked, multicenter trial in the United States . Ophthalmology. 103:1996;138-147.
2. Alm A. The potential of prostaglandin derivates in glaucoma therapy. Curr Opin Ophthalmol. 4:1993;44-50.
3. Alm A., Villumsen J., Tornquist P., et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. Ophthalmology. 100:1993;1312-1317.
4. Camras C., Schumer R., Marsk A., et al. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol. 110:1992;1733-1738.
5. 2α-isopropyl ester to latanoprost a review of the development of Xalatan. The Proctor Lecture . Invest Ophthalmol Vis Sci. 42:2001;1134-1145.
6. Stjernschantz J.W. Phenyl substituted prostaglandin analogues for glaucoma treatment. Drugs Future. 17:1992;691-704.
7. Netland P.A., Landry T., Sullivan E.K., et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 132:2001;472-484.
8. Gandolfi S., Simmons S.T., Sturm R., Chen K., Vanderburgh A.M. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 18:2001;110-121.
9. Rosner B. Fundamentals of biostatistics. 1982;Duxbury Press, Boston,: 301-304.
10. Siegel S. Non parametric statistics. Series in psychology. 1956;McGraw Hill, New York,: 63-67.
11. Book S.A. Essentials of statistics. 1978;McGraw Hill, New York.
12. Stewart W.C., Stewart J.A., Holmes K.T., Leech J.N. Differences in ocular surface irritation between timolol hemihydrate and maleate. Am J Ophthalmol. 130:2000;712-716.
13. Woodward D.F., Krauss A.H.P., Chen J., et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 45:2001;S337-S345.
14. Sherwood M., Brandet J. Six-month comparison of bimatoprost once daily and twice daily with timolol twice daily in patients with elevated IOP. Surv Ophthalmol. 14:2001;S361-S368.
15. Resul B, Stjernschantz J. Structure-activity relationships of prostaglandin analogues as ocular hypotensive agent. Current Opinion in Therapeutic Patients. 1993;781-795.